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ABSTRACT
OBJECTIVES This study sought to better understand the discrepant results of 2 trials of serelaxin on acute heart failure
(AHF) and short-term mortality after AHF by analyzing causes of death of patients in the RELAX-AHF-2 (Efﬁcacy, Safety
and Tolerability of Serelaxin When Added to Standard Therapy in AHF-2) trial.
BACKGROUND Patients with AHF continue to suffer signiﬁcant short-term mortality, but limited systematic analyses
of causes of death in this patient population are available.
METHODS Adjudicated cause of death of patients in RELAX-AHF-2, a randomized, double-blind, placebo-controlled
trial of serelaxin in patients with AHF across the spectrum of ejection fraction (EF), was analyzed.
RESULTS By 180 days of follow-up, 11.5% of patients in RELAX-AHF-2 died, primarily due to heart failure (HF) (38% of
all deaths). Unlike RELAX-AHF, there was no apparent effect of treatment with serelaxin on any category of cause of
death. Older patients ($75 years) had higher rates of mortality (14.2% vs. 8.8%) and noncardiovascular (CV) death (27%
vs. 19%) compared to younger patients. Patients with preserved EF ($50%) had lower rates of HF-related mortality
(30% vs. 40%) but higher non-CV mortality (36% vs. 20%) compared to patients with reduced EF.
CONCLUSIONS Despite previous data suggesting beneﬁt of serelaxin in AHF, treatment with serelaxin was not found
to improve overall mortality or have an effect on any category of cause of death in RELAX-AHF-2. Careful adjudication of
events in the serelaxin trials showed that older patients and those with preserved EF had fewer deaths from HF or sudden
death and more deaths from other CV causes and from noncardiac causes. (Efﬁcacy, Safety and Tolerability of Serelaxin
When Added to Standard Therapy in AHF [RELAX-AHF-2]; NCT01870778) (J Am Coll Cardiol HF 2020;8:999–1008)
© 2020 by the American College of Cardiology Foundation.
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ospitalization for acute heart fail-

randomized 1,161 patients with AHF and demon-

ure (AHF) is associated with signif-

strated

icant

long-term

endpoint) as well as lower CV mortality (1). A sub-

morbidity and mortality, and to date no spe-

sequent analysis of adjudicated cause of death in

ciﬁc therapy has been developed to improve

these patients revealed that improved survival in

these outcomes. Given that many patients

the serelaxin arm of RELAX-AHF was primarily

HF = heart failure

with heart failure (HF) are older and have a

mediated by reduction in “other CV deaths” (which

HFpEF = heart failure with

high burden of comorbidities, the period af-

itself was largely driven by a reduction in stroke),

ter hospitalization is marked by a variety of

with a modest reduction in sudden cardiac death

competing risks for both cardiovascular (CV)

(SCD) (6).

AND ACRONYMS
AHF = acute heart failure
CV = cardiovascular
EF = ejection fraction

preserved ejection fraction

HFrEF = heart failure with
reduced ejection fraction
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(the

primary

and non-CV events. Improved understanding

These ﬁndings led to a larger global trial of 6,545

of the speciﬁc causes of mortality after AHF

patients, RELAX-AHF-2, which was designed to test

may help identify strategies for better addressing

the hypothesis that early administration of serelaxin

poor outcomes in these patients.

would reduce CV mortality at 180 days and worsening

SCD = sudden cardiac death

The RELAX-AHF (Efﬁcacy, Safety and Tolerability

HF through 5 days compared to placebo (2). Despite

of Serelaxin When Added to Standard Therapy in

the promising ﬁndings of RELAX-AHF, RELAX-AHF-2

AHF) and RELAX-AHF-2 studies were global, phase

failed to conclusively demonstrate beneﬁts on either

III, randomized clinical trials evaluating the safety

of these outcomes. In the current analysis, our pri-

and efﬁcacy of serelaxin, a recombinant form of

mary goals were to utilize data on adjudicated cause

human relaxin-2, in patients hospitalized with AHF

of death from the RELAX-AHF-2 trial to (1) inform

(1,2). The hormone relaxin contributes to many of

understanding of the discrepant results of the

the

including

RELAX-AHF and RELAX-AHF-2 studies; and (2)

decreased systemic vascular resistance, increased

identify potential opportunities to better target

renal blood ﬂow, and augmented cardiac output

therapies after AHF hospitalization, especially in

(3,4).

possibly

previously understudied groups (e.g., the elderly and

anti-

patients with HF with preserved ejection fraction

CV

include

adaptations

Additional

of

pregnancy,

pleotropic

anti-inﬂammatory,

properties
angiogenic,

ischemic, and antiﬁbrotic effects (4,5). RELAX-AHF

[HFpEF]).

F I G U R E 1 Categorical Representation of Cause of Death in RELAX-AHF-2 Compared to RELAX-AHF

Comparison of causes of death between RELAX-AHF-2 and RELAX-AHF. In total, 755 of 6,545 patients (11.5%) in RELAX-AHF2 and 107 of
1,161 patients (9.2%) in RELAX-AHF died by 180 days of follow-up. Both trials had similar proportions of patients in 4 categories of death
(p ¼ 0.2370). Other cardiovascular (CV) deaths include CV deaths not attributable to heart failure (HF) or sudden cardiac death (SCD) (e.g.,
acute coronary syndrome, cerebrovascular accident, etc.). Non-CV deaths represent all other deaths (e.g., renal failure, sepsis, etc.). RELAXAHF ¼ Efﬁcacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF.
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METHODS
RELAX-AHF-2

T A B L E 1 Cause of Death in RELAX-AHF-2

was

a

multicenter,

Serelaxin
(n ¼ 3,274)

Placebo
(n ¼ 3,271)

Total
(N ¼ 6,545)

All

367 (11.2)

388 (11.9)

755 (11.5)

CV

285 (8.7)

290 (8.9)

575 (8.8)

157 (4.8)

290 (4.4)

randomized,

double-blind, placebo-controlled, event-driven trial
that randomized patients admitted to the hospital for
AHF with symptoms of dyspnea, congestion on chest

HF or cardiogenic shock

133 (4.1)

radiography, elevation in natriuretic peptide con-

Sudden cardiac death

68 (2.0)

70 (2.1)

138 (2.1)

centrations,

Other

84 (2.6)

63 (1.9)

147 (2.2)

systolic

blood

pressure

at

least

125mm Hg, and mild-to-moderate renal impairment

Cerebrovascular accident

21 (0.6)

12 (0.4)

33 (0.5)

(estimated glomerular ﬁltration rate 25 to 75 ml/

Acute coronary syndrome

16 (0.5)

9 (0.3)

25 (0.4)

min/1.73 m 2 body surface area) to serelaxin or

Procedure complication

6 (0.2)

13 (0.4)

19 (0.3)

Systemic or pulmonary embolism

6 (0.2)

4 (0.1)

10 (0.1)

Peripheral arterial disease

2 (0.1)

0 (0.0)

2 (0.0)

Presumed CV/unknown

33 (1.0)

25 (0.8)

58 (0.9)

matching placebo. The trial design and primary results have been previously reported (2,7). In brief,
patients who remained symptomatic after 1 dose of

82 (2.5)

98 (3.0)

180 (2.8)

intravenous furosemide (at least 40 mg or equivalent)

Infectious

29 (0.9)

31 (1.0)

60 (0.9)

were

randomization. Randomization

Pulmonary

18 (0.6)

25 (0.8)

43 (0.7)

occurred within 16 h of presentation or ﬁrst intrave-

Malignancy

9 (0.3)

21 (0.6)

30 (0.5)

nous administration of loop diuretic in a 1:1 ratio.

Gastrointestinal

8 (0.2)

7 (0.2)

15 (0.2)

Renal

6 (0.2)

5 (0.2)

11 (0.2)

Neurological

5 (0.2)

2 (0.1)

7 (0.1)

Other

7 (0.2)

7 (0.2)

14 (0.2)

eligible

1001
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for

Patients received either serelaxin at a dose of
30 m g/kg/day or matching placebo, beginning no more

Non-CV

than 4 h after randomization, for up to 48 h. Serelaxin
dosing was adjusted or discontinued in response to
decreases in systolic blood pressure according to
protocol. The ethics committee at each participating

Values are n (%). Cause of death in RELAX-AHF-2 by treatment arm with etiologies of “other” CV
and non-CV death.
CV ¼ cardiovascular; HF ¼ heart failure; RELAX-AHF-2 ¼ Efﬁcacy, Safety and Tolerability of
Serelaxin When Added to Standard Therapy in AHF-2.

center approved the study, and patients provided
written informed consent.
The trial had 2 primary efﬁcacy endpoints: death
from CV causes at 180 days and worsening HF
(deﬁned as worsening signs and symptoms of HF
necessitating the addition or escalation of HF therapy) at 5 days. Secondary endpoints included death
from any cause at 180 days, length of index hospital
stay, and a composite of death from CV causes or
rehospitalization for HF or renal failure at 180 days.
EVENT ADJUDICATION. A clinical events committee

blinded to treatment allocation adjudicated all deaths

distribution). Deaths were grouped into pre-deﬁned
categories, similar to those used for the cause of
death analysis of RELAX-AHF (6). CV causes of death
included HF, SCD, and other CV death. Other CV
deaths included cerebrovascular events (ischemic,
hemorrhagic, or unknown stroke), acute coronary
syndrome, systemic or pulmonary embolism, CV
procedure complication, or presumed/unknown CV
death. The ﬁnal category of non-CV deaths included
all other causes of death (e.g., sepsis, malignancy,
renal failure, etc.).

and hospitalizations that occurred up to 180 days. For

Cox proportional hazards models were used to

each event, the committee reviewed the case report

assess the treatment effect of serelaxin on each cause

form and all available relevant source documents

of death (based on cause-speciﬁc hazards). All pa-

from the medical record, including hospital notes,

tients were included in these models with follow-up

discharge summaries, autopsy reports, and death

time censored at the last date known alive until

certiﬁcates. Deﬁnitions of each cause of death were

180 days or date of death from another mode, and

previously developed by the clinical events commit-

hazard ratios with associated 95% conﬁdence in-

tee and approved by the study executive committee.

tervals estimated from these models are presented.

Speciﬁc event deﬁnitions and the adjudication pro-

The p values from the log-rank test are presented.

cess were generally the same in both RELAX-AHF

Chi-square tests were used to determine differences

studies.

adjudicate

between cause-of-death categories in the 2 RELAX

deaths are summarized in Supplemental Appendix

trials and by age and ejection fraction (EF) in RELAX-

A (1,6).

AHF-2. The Fine and Gray subdistribution hazard

STATISTICAL ANALYSIS. Baseline characteristics are

competing risk model was ﬁtted to obtain the cumu-

described using appropriate descriptive statistics

lative incidence function for each cause of death for

(percentage, mean  SD, or median [interquartile

both RELAX trials. SAS release 9.4 (SAS Institute, Inc.,

range] depending on the type of variable and its

Cary, North Carolina) was used for analyses.

Speciﬁc

deﬁnitions

used

to
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T A B L E 2 Demographics of Patients by Vital Status and Cause of Death

Survivors
(n ¼ 5,790)

Nonsurvivors
(n ¼ 755)

HF Death
(n ¼ 290)

Sudden Death
(n ¼ 138)

Other CV Death
(n ¼ 147)

Non-CV Death
(n ¼ 180)

72.6  11.2

76.2  10.5

76.7  10.2

73.2  12.0

75.4  10.5

78.4  9.4

Weight, kg

84.5  20.0

81.5  20.8

82.2  20.5

83.7  22.9

78.8  19.2

80.9  20.8

SBP, mm Hg*

146.4  16.8

144.4  15.8

141.8  14.4

145.9  17.2

145.3  16.8

146.9  15.4

DBP, mm Hg*

82.4  14.2

80.1  13.4

77.9  12.5

83.3  14.1

82.3  14.8

79.6  12.6

Heart rate, beats/min*

83.5  17.1

83.7  16.5

83.7  15.7

82.4  16.6

84.9  17.2

83.7  17.3

Respiratory rate, breaths/min*

21.8  4.5

22.6  5.3

22.4  4.8

23.3  5.9

22.8  5.0

22.4  5.7

39.9  13.8

39.3  14.4

38.6  13.9

38.2  14.5

41.0  16.5

40.2  13.7

Age, yrs

Most recent EF, %
Number of admissions for HF in past year
Men
White

1.1  1.2

1.3  1.2

1.4  1.3

1.1  1.0

1.2  1.1

1.2  1.2

3,450 (59.6)

458 (60.7)

171 (59.0)

94 (68.1)

81 (55.1)

112 (62.2)

5,307 (91.7)

709 (93.9)

273 (94.1)

127 (92.0)

139 (94.6)

170 (94.4)

EF <40%

1,364/2,772 (49.2)

195/366 (53.3)

84/152 (55.3)

37/71 (52.1)

32/65 (49.2)

42/78 (53.8)

Admitted to hospital for
HF in past year

2,896/5,397 (53.7)

442/718 (61.6)

191/280 (68.2)

88/134 (65.7)

71/138 (51.4)

92/166 (55.4)

Asthma

261 (4.5)

38 (5.0)

17 (5.9)

9 (6.5)

6 (4.1)

6 (3.3)

Blood transfusion

446 (7.7)

71 (9.4)

27 (9.3)

12 (8.7)

12 (8.2)

20 (11.1)

Medical history

Bronchitis

447 (7.7)

60 (7.9)

28 (9.7)

9 (6.5)

12 (8.2)

11 (6.1)

CABG

833 (14.4)

128 (17.0)

54 (18.6)

16 (11.6)

23 (15.6)

35 (19.4)

Cardiac pacemaker insertion

727 (12.6)

115 (15.2)

46 (15.9)

7 (5.1)

16 10.9)

46 (25.6)

Cardiac resynchronization therapy

219 (3.8)

35 (4.6)

16 (5.5)

6 (4.3)

6 (4.1)

7 (3.9)

Cerebrovascular accident

870 (15.0)

138 (18.3)

51 (17.6)

27 (19.6)

25 (17.0)

35 (19.4)

Chronic obstructive pulmonary disease

891 (15.4)

150 (19.9)

60 (20.7)

22 (15.9)

27 (18.4)

41 (22.8)

Depression

544 (9.4)

79 (10.5)

31 (10.7)

12 (8.7)

14 (9.5)

22 (12.2)

Hyperlipidemia

2,955 (51.0)

356 (47.2)

135 (46.6)

63 (45.7)

72 (49.0)

86 (47.8)

Hypertension

164 (91.1)

5,191 (89.7)

684 (90.6)

263 (90.7)

121 (87.7)

136 (92.5)

Hyperthyroidism

198 (3.4)

22 (2.9)

8 (2.8)

2 (1.4)

2 (1.4)

10 (5.6)

Hypothyroidism

626 (10.8)

78 (10.3)

31 (10.7)

11 (8.0)

17 (11.6)

19 (10.6)

Implantable deﬁbrillator insertion

508 (8.8)

68 (9.0)

26 (9.0)

15 (10.9)

12 (8.2)

15 (8.3)

Ischemic heart disease

1,875 (32.4)

269 (35.6)

116 (40.0)

49 (35.5)

53 (36.1)

51 (28.3)

Percutaneous coronary intervention

1,379 (23.8)

193 (25.6)

71 (24.5)

41 (29.7)

36 (24.5)

45 (25.0)

740 (12.8)

137 (18.1)

49 (16.9)

26 (18.8)

20 (13.6)

42 (23.3)

2,637/5,787 (45.6)

376/755 (49.8)

150/290 (51.7)

63/138 (45.7)

78/147 (53.1)

85/180 (47.2)

Peripheral arterial disease
Diabetes mellitus
eGFR (ml/min)
NT-proBNP (pg/ml)

52  14.3

46.1  14.0

44.5  13.3

48.6  14.4

47.1  14.3

45.8  14.5

5,800 (3,444–
9,008)

9,006 (4,702–
13,509)

9,006 (4,919–
13,509)

9,006 (4,631–
13,509)

9,006 (4,593–
13,509)

7,821 (4,332–
13,509)

Values are mean  SD, n (%), n/N, or median (interquartile range Q1–Q3). Baseline demographics of survivors and nonsurvivors, with nonsurvivors further characterized by cause of death. *Vital signs at
screening visit.
CABG ¼ coronary artery bypass grafting; DBP ¼ diastolic blood pressure; EF ¼ ejection fraction; eGFR ¼ estimated glomerular ﬁltration rate; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide;
SBP ¼ systolic blood pressure; other abbreviations as in Table 1.

RESULTS

proportions of patients in the 4 categories of death
(p ¼ 0.2370). In RELAX-AHF-2, among the 147 pa-

Of the 6,545 patients included in the intention-to-

tients classiﬁed as having “other CV death” (i.e.,

treat analysis of RELAX-AHF-2, 755 (11.5%) died

not from HF or SCD), 33 had cerebrovascular acci-

within 180 days. The majority of deaths were due

dents, 25 had acute coronary syndromes, 19 deaths

to CV causes (n ¼ 575; 76% of total deaths),

were related to CV procedures, and 58 were clas-

attributable most commonly to HF (n ¼ 290; 38% of

siﬁed as unknown/presumed CV death (Table 1).

total

deaths),

followed

by

“other

CV

death”

Overall, 180 patients (24% of total deaths; 2.8% of

(n ¼ 147; 20% of total deaths) and SCD (n ¼ 138;

the

18% of total deaths) (Figure 1). By comparison, 107

including

of 1,161 of patients (9.2%) in RELAX-AHF died by

(including pneumonia), 30 malignancy, and 11 renal

180 days of follow-up. Both trials had similar

failure (Table 1).

trial

population)
60

died

infection,

43

of

non-CV
pulmonary

causes,
cause
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Baseline characteristics of survivors and nonsurvivors by cause of death are outlined in Table 2.

F I G U R E 2 Treatment Effects of Serelaxin by Cause of Death in Both RELAX-AHF Trials

Nonsurvivors were older, more frequently had previous hospitalization for HF in the preceding year,
and had a higher burden of comorbidities, including
history of coronary bypass surgery, cerebrovascular
accident, obstructive pulmonary disease, and peripheral arterial disease. They also had worse renal
function (lower estimated glomerular ﬁltration rate)
and higher natriuretic peptide levels.
There was no apparent effect of treatment with
serelaxin on any category of cause of death (Figures 2
and 3, Supplemental Table 1) in RELAX-AHF-2. Patients in RELAX-AHF had a numerically higher proportions of deaths in the SCD and other CV death

Hazard ratios with 95% conﬁdence intervals for serelaxin versus placebo for overall

categories, whereas patients in RELAX-AHF-2 had a

mortality and each of the categories of cause of death. Abbreviations as in Figure 1.

numerically higher proportion of deaths due to nonCV causes (Figure 1).
AGE AND CAUSE OF DEATH. The mean age of pa-

tients enrolled in RELAX-AHF-2 was approximately
73 years, and more than one-half of patients were $75
years old (n ¼ 3,302), allowing unique insight into
cause of death in older patients with AHF. To further
understand this relationship, we analyzed cause of
death in older versus younger patients (Table 3). As
expected, the age group $75 years had higher mortality (n ¼ 468; 14.2% of cohort) than the younger
group of patients (n ¼ 287; 8.8% of cohort). The distribution of cause of death also differed by age group,
with more SCD seen in younger patients and more
non-CV deaths in older patients.

therapeutic interventions. We aimed to use adjudicated cause of death data from the RELAX-AHF-2
study to better understand the discrepant results of
the RELAX-AHF and RELAX-AHF-2 studies and
identify potential opportunities to better target
therapies in patients with AHF (Central Illustration).
Unlike RELAX-AHF, in which treatment with serelaxin reduced 180-day all-cause and CV mortality,
primarily through reduction in “other CV deaths,”
serelaxin use did not have a signiﬁcant impact on any
cause of death in RELAX-AHF-2. Multiple potential
explanations for the different results from RELAXAHF and RELAX-AHF-2 include differences in patient population, investigative sites, trial design, and

CAUSE OF DEATH IN HFpEF VERSUS HFrEF. RELAX-

the play of chance. In a previously published analysis,

AHF-2 enrolled a heterogeneous AHF population

the reduction in stroke deaths observed in RELAX-

across the spectrum of left ventricular EF. To better

AHF was postulated to be due to improved blood

understand how differences in EF have an impact on

pressure control or favorable vascular changes, and

cause of death after AHF, we assessed cause of death

putative mechanisms for a marginal reduction in SCD

based on preserved EF ($50%; n ¼ 1,595) versus
reduced EF (<50%; n ¼ 4,533) in patients in RELAXAHF-2 (Table 4) in whom EF was available at enrollment (n ¼ 6,128). By 180 days of follow-up, 498 pa-

including reduction in ischemia or contribution of
additional pleotropic effects of serelaxin, including
anti-inﬂammatory,

antiﬁbrotic,

and

vasodilatory

properties (6). We did not conﬁrm a treatment effect

tients (11.0%) with heart failure with reduced ejection

of serelaxin on these speciﬁc causes of death in

fraction (HFrEF) died, and 183 patients (11.5%) with

RELAX-AHF-2, suggesting that it is unlikely that ser-

HFpEF died. Patients with reduced versus preserved

elaxin therapy conferred an important beneﬁt with

EF had signiﬁcantly different proportions of patients

regard to these endpoints. Despite the intention to

in each category of death, with HFrEF patients having

enroll similar patients, patients in RELAX-AHF-2 had

more HF deaths (40% vs. 30%) and HFpEF patients

a 33% higher rate of non-CV death (24% vs. 18% of

having

total deaths) than patients in RELAX-AHF. The higher

more

non-CV

deaths

(36%

vs.

20%) (p < 0.0001).

incidence of non-CV death in RELAX-AHF-2 suggests

DISCUSSION

that these patients may have had higher non-CV (and
thus were less modiﬁable with a HF intervention)

Improved insight into the speciﬁc causes of death

competing risk than patients in RELAX-AHF.

after AHF can inform understanding of the results of

IMPLICATIONS FOR MANAGEMENT OF AHF AND

speciﬁc clinical trials and provide direction for new

FUTURE TRIALS. In comparison to chronic HF, the
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F I G U R E 3 Competing Risk Analysis of Both RELAX-AHF Trials

Competing risk analysis demonstrates probability of dying from each cause of death over follow-up for serelaxin and placebo arms of RELAX-AHF and RELAX-AHF-2.
Abbreviations as in Figure 1.

period after an AHF hospitalization is a higher risk

that a signiﬁcant portion of early deaths after AHF are

period, sometime termed the “vulnerable phase” (8).

HF-related (11).

In comparison to patients with chronic HF, patients

Similar to other trials of AHF, the ﬁndings observed

with AHF have higher short-term event rates and a

in RELAX-AHF-2 suggest that short-term therapies

higher proportion of HF deaths versus other causes of

are unlikely to have a lasting impact on long-term

death (9). In RELAX-AHF-2, patients had a 180-day

mortality compared to standard of care (12,13). How-

mortality of 11.5% after AHF hospitalization, with a

ever, a hospitalization for AHF may be an opportune

large proportion of deaths due to HF (38%). Similarly,

time to initiate (or titrate) chronic guideline-directed

causes of death in the EVEREST (Efﬁcacy of Vaso-

medical therapy, a strategy that has generated some

pressin Antagonism in Heart Failure Outcome Study

evidence of clinical beneﬁt (14–17).

with Tolvaptan) trial were predominantly related to

IMPLICATIONS FOR HF MANAGEMENT IN THE ELDERLY.

HF (41%) and SCD (26%) (10). To our knowledge, the

Older patients with HF tend to have a greater burden

current analysis is the largest to date examining

of comorbidities and other competing risks than do

adjudicated cause of death in patients after AHF

younger patients with HF. With an average age of 73

hospitalization and supports previous data indicating

years, which is older than in many comparable AHF
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studies (68 years in TRUE-HF [Efﬁcacy and Safety of
Ularitide for the Treatment of Acute Decompensated

T A B L E 3 Cause of Death by Age in RELAX-AHF-2

Age <75 yrs
(n ¼ 287)

Age $75 yrs
(n ¼ 468)

p Value*
(<75 yrs vs. $75 yrs)

HF death

103 (36)

187 (40)

0.0014

SCD

70 (24)

68 (15)

Decompensated Heart Failure]), the RELAX-AHF-2

Other CV death

60 (21)

87 (19)

program provided a unique opportunity to assess

Non-CV death

54 (19)

126 (27)

cause of death in older patients with HF (12,13).

Total

287 (100)

468 (100)

Heart Failure] and 67 years in ASCEND-HF [DoubleBlind, Placebo-Controlled, Multicenter Acute Study of
Clinical Effectiveness of Nesiritide in Subjects With

Compared to previous studies assessing cause of
death in AHF patients with HFrEF (13.2% at median
follow-up of 9.9 months) and across the spectrum of
EF (11.9% at 6 months), our rate of non-CV death at
180 days was higher (24%) (10,11), which may be

Values are n (%), unless otherwise indicated. In RELAX-AHF-2, 8.8% (287 of 3,243) of patients
age <75 years and 14.2% (468 of 3,302) of patients age $75 years died. These groups had
signiﬁcantly different proportions of patients in the 4 categories of cause of death, with a
higher proportion of sudden death at age <75 years and a higher proportion of non-CV death at
age $75 years. *Based on Chi-square test.
SCD ¼ sudden cardiac death; other abbreviations as in Table 1.

attributable to the more contemporary nature of and
improved standard of HF care within our trial, but
also inclusion of a more elderly population. Our study

HFrEF tend to have higher rates of CV and HF read-

demonstrates that older patients in RELAX-AHF-2, in

missions, whereas patients with HFpEF tend to have

particular, had signiﬁcantly higher proportions of

more non-CV readmissions and non-CV death (22–24).

non-CV death compared to younger patients (27% vs.

Within our HFpEF group, rates of non-CV death (36%)

19%) and lower relative and absolute rates of CV

were similar to those in the CHARM-Preserved (Can-

death. Hospitalization for AHF may represent an op-

desartan in Heart failure Assessment of Reduction in

portunity to coordinate multimodal care for elderly

Mortality and Morbidity) trial (29%) (25), I-Preserve

patients with additional comorbidities in order to

(Irbesartan in Heart Failure With Preserved Ejection

mitigate some non-CV deaths (18).

Fraction Study) trial (30%) (26), and TOPCAT (Spi-

Younger patients had more from SCD (24% vs.

ronolactone for Heart Failure with Preserved Ejection

15%). A recent trial assessing the beneﬁt of implant-

Fraction) trial (28%) (27). In the EVEREST trial, which

able cardioverter-deﬁbrillators in patients with non-

enrolled patients with EF #40%, non-CV death

ischemic cardiomyopathy with depressed EF found

accounted for only 13.2% of deaths during follow-up.

that

In totality, these ﬁndings demonstrate that patients

prophylactic

implantable

cardioverter-

deﬁbrillator insertion in this population was not

with both HFrEF and HFpEF have signiﬁcant short-

associated with long-term reduction in mortality (19).

term mortality, with a higher contribution of non-

However, when assessed speciﬁcally by age, younger

CV causes in those with HFpEF.

patients with fewer comorbidities tended to derive

Heterogeneity of the tested population is a

beneﬁt whereas older patients with more comorbid-

commonly postulated reason for failure of previous

ities did not (20). Although these ﬁndings are in a

HFpEF trials. Biopsy studies indicate that a substan-

different population, our analysis supports their

tial proportion of these patients may have cardiac

plausibility.

amyloidosis (28) or represent other distinct phe-

IMPLICATIONS FOR MANAGEMENT OF HFpEF. Pa-

nogroups that may have different risk proﬁles and

tients with HFpEF account for a growing proportion
of patients hospitalized with AHF (21). Although
RELAX-AHF-2 enrolled mostly patients with reduced

T A B L E 4 Cause of Death by EF in RELAX-AHF-2

EF (74%), those with preserved EF had a similar

EF <50% (n ¼ 498) EF $50% (n ¼ 183)

incidence of 180-day mortality (11.0% vs. 11.5%) but

HF death

200 (40)

54 (30)
26 (14)

with signiﬁcantly different proportions of patients in

SCD

101 (20)

each category of death. Patients with HFrEF had a

Other CV death

99 (20)

38 (21)

higher proportion of patients with HF death (40% vs.

Non-CV death

98 (20)

65 (36)

30%), whereas those with HFpEF had a higher pro-

Total

498 (100)

183 (100)

portion of patients with non-CV death (36% vs. 20%).
Our ﬁndings are in line with previous studies,
demonstrating that (1) patients have higher shortterm mortality post-AHF, regardless of EF (11); (2)
long-term mortality is similar between HFrEF and

p Value*

<0.0001

Values are n (%), unless otherwise indicated. Patients with reduced EF (<50%;
n ¼ 4,533) vs. preserved EF ($50%; n ¼ 1,595) had signiﬁcantly different proportions of patients in the 4 categories of cause of death. Patients with EF <50%
had a signiﬁcantly higher proportion of patients with HF death, whereas those with
EF $50% had signiﬁcantly higher proportion of patients with non-CV death.
*Based on Chi-square test.
Abbreviations as in Tables 1 to 3.

HFpEF patients post-AHF (22); but (3) patients with
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C E N T R A L IL LU ST R A T I O N Causes of Death in the Efﬁcacy, Safety and Tolerability of Serelaxin When
Added to Standard Therapy in AHF-2 Study
800

11.5%
(n = 755/6,545)

700
180 (24%)
p = NS

Number of Deaths

600

500

p = 0.0014

14.2%
(n = 468/3,302)

147 (20%)

11.2%
(n = 367/3,274)

400

p < 0.0001

138 (18%)
82 (22%)

300

84 (23%)

200

11%
(n = 498/4,533)
98 (20%)

11.9%
(n = 388/3,271)

126 (27%)

98 (25%)

8.8%
(n = 287/3,243)

63 (16%)

54 (19%)
60 (21%)

70 (18%)

99 (20%)
87 (19%)
101 (20%)
68 (14%)

68 (19%)
290 (38%)

65 (36%)

70 (24%)

100
133 (36%)

187 (40%)

157 (41%)

11.5%
(n = 183/1,595)

200 (40%)

103 (36%)

38 (21%)
26 (14%)
54 (30%)

0
Relax-AHF 2
HF Death

Serelaxin

Age <75

Placebo

Sudden Cardiac Death

Age ≥75

Other Cardiovascular Death

EF <50%

EF ≥50%

Non-Cardiovascular Death

Loungani, R.S. et al. J Am Coll Cardiol HF. 2020;8(12):999–1008.

In an analysis of adjudicated cause of death in a large, contemporary, heterogeneous acute heart failure (AHF) population across the spectrum of ejection
fraction (EF), 180-day mortality was 11.5% and was primarily due to heart failure (HF) (38% of all deaths). Older patients had higher rates of death than
younger patients (14.2% vs. 8.8%) and suffered more from non cardiovascular (CV) death. Patients with preserved EF had rates of death similar to those
with reduced EF (11.5% vs. 11.0%) but also had more non-CV death. RELAX-AHF-2 ¼ Efﬁcacy, Safety and Tolerability of Serelaxin When Added to
Standard Therapy in AHF-2.

responses to treatment (29–31). Patients with HFpEF

Heart Failure With Preserved Ejection Fraction [FAIR-

tend to have a higher burden of non-CV comorbidities

HFpEF]; NCT03074591) on outcomes in HFpEF pa-

than those with HFrEF, and HFpEF phenogroups with

tients are ongoing. Furthermore, routine preventa-

a high prevalence of these comorbidities tend to fare

tive care strategies—optimal control of diabetes,

clinically worse (24,29,30,32). Combined with evi-

recommended cancer screening, vaccine administra-

dence that HFpEF patients have more non-CV hos-

tion—all are important adjuncts to HF care and may

pitalization and death, clinical care and future trials

play a role in reducing morbidity and mortality in

should incorporate strategies focused on mitigating

these patients.

these comorbidities to improve outcomes. Trials
assessing the impact of sodium glucose cotransporter

CONCLUSIONS

2 inhibitors (Dapagliﬂozin Evaluation to Improve the
LIVEs of Patients With PReserved Ejection Fraction

Our analysis of cause of death in RELAX-AHF-2 did

Heart Failure [DELIVER]; NCT03619213) and intrave-

not identify an effect of serelaxin on any speciﬁc

nous iron (Effect of IV Iron in Patients With

cause of death in the population studied. An
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